

383 Views | 41 CrossRef citations to date | 6 Altmetric

Articles

Small-area variations in sales of TNF inhibitors in Sweden between 2000 and 2009

M Neovius, A Sundström, JF Simard, B Wettermark, T Cars, N Feltelius, ... show all
Pages 8-15 | Accepted 13 May 2010, Published online: 18 Oct 2010

Cite this article <https://doi.org/10.3109/03009742.2010.493895>

Sample our Medicine, Dentistry, Nursing & Allied Health Journals >> Sign in here to start your access to the latest two volumes for 14 days

Full Article | Figures & data | References | Citations | Metrics

Reprints & Permissions | [Read this article](#)

Abstract

Objectiv... factor (T... Methods... retrieved... drugs di... retri... (sulfasa... therape... of biolog... registers... ecrosis... mab were... s data on... ata were... orders... erent... penetration... nationwide

We Care About Your Privacy

We and our 843 partners store and/or access information on a device, such as unique IDs in cookies to process personal data. You may accept or manage your choices by clicking below, including your right to object where legitimate interest is used, or at any time in the privacy policy page. These choices will be signaled to our partners and will not affect browsing data. [Privacy Policy](#)

We and our partners process data to provide:

Use precise geolocation data. Actively scan device characteristics for identification. Store and/or access information on a device. Personalised advertising and content, advertising and content measurement, audience research and services development.

List of Partners (vendors)

I Accept

Essential Only

Show Purpose





Results: From 2000 to 2009, annual TNF inhibitor sales increased 9-fold from 195 to 1779 million SEK (0.7–5.0% of total drug expenditure). The county variation in sales per capita, initially 6.2-fold (coefficient of variation 42%), decreased to 2.3-fold in 2009 (24%). During the same period, total drug expenditure per capita remained at a 1.2-fold county variation (4–6%). Sales per capita variations of non-biologic treatments against chronic inflammatory diseases ranged from 1.5 to 1.8 (12–16%). For trastuzumab, a 3.2-fold variation (30%) was observed in 2009. At the patient level, there was a 2-fold county variation (from 10% to 21%) in biologic penetration in RA. County-specific sales per capita were associated with mean RA duration ($r = -0.52$, $p = 0.015$) and C-reactive protein at treatment initiation ($r = -0.49$, $p = 0.025$), while pain was borderline significant ($r = -0.43$, $p = 0.055$).

Conclusions: Despite universal access to treatment, substantial but decreasing small-area variations were observed. Although geographic variations are anticipated initially, their persistence calls for investigation of patient equity and treatment appropriateness as counties seem to have different initiation thresholds.

Acknowledgements

We thank Anna Lindhé, Västra Götalandsregionen, and Maj Carlsson, Region Skåne, for providing data on the allocation of county sales of TNF inhibitors by indication.

The ART... Swedish
Biologics... the
mainten... ceived
funding, ... ring-Plough,
BMS, Wy...
The... (University), L
Cöste... Itelius
(Medical... University),
L Klares... apaa-
Dahlqvist... ven
(Karolins...



Related Research Data

Assessment of RA Incidence in Sweden

Source: Wiley

Inflammatory Bowel Disease and Parkinson's Disease: A Nationwide Swedish Cohort Study.

Source: Oxford University Press (OUP)

Biological Therapies in Immune-Mediated Inflammatory Diseases: Can Biosimilars Reduce Access Inequities?

Source: Frontiers Media SA

SCLE and its association with drugs

Source: Wiley

Nationwide prevalence of inflammatory bowel disease in Sweden: a population-based register study

Source: Wiley

Cost-effectiveness of infliximab versus conventional combination treatment in methotrexate-refractory early rheumatoid arthritis: 2-year results of the register-enriched randomised controlled SWEFOT trial

Source: BMJ

Prevalence of paediatric inflammatory bowel disease in Sweden: a nationwide population-based register study

Source: Springer Science and Business Media LLC

Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 1—Biosimilar and Originator Infliximab in the Hospital Setting

Source

Quali

Source

Linkin



Related

Information for

- Authors
- R&D professionals
- Editors
- Librarians
- Societies

Opportunities

- Reprints and e-prints
- Advertising solutions
- Accelerated publication
- Corporate access solutions

Open access

- Overview
- Open journals
- Open Select
- Dove Medical Press
- F1000Research

Help and information

- Help and contact
- Newsroom
- All journals
- Books

Keep up to date

Register to receive personalised research and resources by email

 Sign me up



✕